1-9 of 9
Joshua Lehrer-Graiwer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cedar Trial in Progress: A First in Human, Phase 1/2 Study of the Correction of a Single Nucleotide Mutation in Autologous HSCs (GPH101) to Convert HbS to HbA for Treating Severe SCD

Julie Kanter, John F. DiPersio, Patrick Leavey, David C. Shyr, Alexis A Thompson, Matthew H. Porteus, Allison Intondi, Premanjali Lahiri, Daniel P. Dever, Alexandria Petrusich, Joshua Lehrer-Graiwer
Journal: Blood
Blood (2021) 138 (Supplement 1): 1864.
https://doi.org/10.1182/blood-2021-152892
Published: 2021
Journal Articles

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Jo Howard, MBBChir, MRCP, FRCPath, Kenneth I. Ataga, MD, R. Clark Brown, MD PhD, Maureen Achebe, MD MPH, Videlis Nduba, MD, Amal El-Beshlawy, MD, Hoda Hassab, MD, Irene Agodoa, MD, Margaret Tonda, PharmD, Sarah Gray, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Elliott Vichinsky, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19.
https://doi.org/10.1182/blood-2020-140553
Published: 2020
Journal Articles

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Satheesh Chonat, MD, Earl Fields, Hannah Baratz, Amanda Watt, Mira Pochron, PhD, Sandy Dixon, Margaret Tonda, PharmD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Clark Brown, MD PhD, David R. Archer, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2281.
https://doi.org/10.1182/blood-2019-129351
Published: 2019
Journal Articles

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Elliott P. Vichinsky, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD, Margaret Tonda, PharmD, Barbara Tong, PhD, Irene Agodoa, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Kenneth I. Ataga, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2313.
https://doi.org/10.1182/blood-2019-129026
Published: 2019
Journal Articles

Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Jo Howard, MB, BChir, Elliott Vichinsky, MD UCSF, Jennifer Knight-Madden, MBBS, PhD, Margaret Tonda, PharmD, Carla Washington, Barbara Tong, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Victor R Gordeuk, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1020.
https://doi.org/10.1182/blood-2019-130802
Published: 2019
Journal Articles

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Russell E. Ware, MD PhD, Clark Brown, MD PhD, Mariane de Montalembert, MD PhD, Margaret Tonda, PharmD, Barbara Tong, PhD, Carolyn Hoppe, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Miguel R. Abboud, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1003.
https://doi.org/10.1182/blood-2019-130767
Published: 2019
Journal Articles

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Clinical Trials & Observations
Jo Howard, Claire Jane Hemmaway, Paul Telfer, D. Mark Layton, John Porter, Moji Awogbade, Timothy Mant, Daniel D. Gretler, Kobina Dufu, Athiwat Hutchaleelaha, Mira Patel, Vincent Siu, Sandra Dixon, Noel Landsman, Margaret Tonda, Joshua Lehrer-Graiwer
Journal: Blood
Blood (2019) 133 (17): 1865–1875.
https://doi.org/10.1182/blood-2018-08-868893
Published: 2019
Journal Articles

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Clark Brown, Carolyn Hoppe, Adlette Inati, Miguel R. Abboud, Winfred Wang, MD, Robert Liem, MD, Gerald Woods, Lewis L. Hsu, Victor R. Gordeuk, MD, Connie Piccone, Richard A. Drachtman, Erica Fong, Sandra Dixon, Margaret Tonda, PharmD, Carla Washington, Joshua Lehrer-Graiwer
Journal: Blood
Blood (2018) 132 (Supplement 1): 509.
https://doi.org/10.1182/blood-2018-99-117510
Published: 2018
Journal Articles

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Elliott Vichinsky, MD, Carolyn Hoppe, Jo Howard, Kenneth I. Ataga, Videlis Nduba, Amal El-Beshlawy, David L. Diuguid, Salam Al-Kindi, Clark Brown, Hoda Hassab, MD, Paul Telfer, Dimitris A. Tsitsikas, Selma Unal, Julie Kanter, MD, Miguel R. Abboud, Victor R. Gordeuk, MD, Joshua Lehrer-Graiwer, Claire Sherman, Margaret Tonda, PharmD, Allison Intondi, Yifah Yaron, Russell E. Ware, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 505.
https://doi.org/10.1182/blood-2018-99-118508
Published: 2018